Pacira Biosciences (NASDAQ:PCRX) Lowered to Sell at BidaskClub

Pacira Biosciences (NASDAQ:PCRX) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, BidAskClub reports.

A number of other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Pacira Biosciences from a “strong-buy” rating to a “hold” rating and set a $47.00 target price for the company. in a research note on Wednesday, January 8th. Cowen reaffirmed a “hold” rating and issued a $41.00 price target on shares of Pacira Biosciences in a research note on Thursday, November 7th. BTIG Research started coverage on shares of Pacira Biosciences in a research note on Wednesday, November 6th. They issued a “buy” rating and a $56.00 price target on the stock. Jefferies Financial Group set a $60.00 price objective on Pacira Biosciences and gave the stock a “buy” rating in a report on Tuesday, October 8th. Finally, Barclays boosted their price objective on Pacira Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Two analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. Pacira Biosciences presently has an average rating of “Hold” and a consensus target price of $52.55.

Pacira Biosciences stock traded up $1.48 during trading on Tuesday, reaching $43.98. The company had a trading volume of 7,225 shares, compared to its average volume of 447,925. The firm has a market capitalization of $1.81 billion, a PE ratio of 151.76, a price-to-earnings-growth ratio of 1.09 and a beta of 1.16. The firm’s 50-day simple moving average is $45.08 and its 200 day simple moving average is $41.47. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.32 and a current ratio of 3.95. Pacira Biosciences has a 1-year low of $34.64 and a 1-year high of $49.50.

Pacira Biosciences (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.35. The company had revenue of $104.69 million during the quarter, compared to analysts’ expectations of $104.88 million. Pacira Biosciences had a net margin of 0.55% and a return on equity of 10.19%. The firm’s revenue for the quarter was up 25.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.31 earnings per share. Analysts anticipate that Pacira Biosciences will post 0.71 EPS for the current year.

In other news, CEO David M. Stack sold 70,000 shares of Pacira Biosciences stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $44.47, for a total value of $3,112,900.00. Also, VP Lauren Bullaro Riker sold 1,176 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $44.14, for a total value of $51,908.64. Following the transaction, the vice president now directly owns 11,640 shares in the company, valued at approximately $513,789.60. The disclosure for this sale can be found here. Insiders sold 81,147 shares of company stock worth $3,610,823 over the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Smith Asset Management Group LP increased its position in Pacira Biosciences by 181.2% during the second quarter. Smith Asset Management Group LP now owns 27,131 shares of the company’s stock worth $1,180,000 after purchasing an additional 17,481 shares during the last quarter. Pictet Asset Management Ltd. grew its holdings in shares of Pacira Biosciences by 10.0% during the 3rd quarter. Pictet Asset Management Ltd. now owns 276,950 shares of the company’s stock worth $10,543,000 after purchasing an additional 25,200 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Pacira Biosciences by 414.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,436 shares of the company’s stock worth $63,000 after purchasing an additional 1,157 shares during the last quarter. Mason Street Advisors LLC acquired a new stake in shares of Pacira Biosciences during the 3rd quarter worth about $538,000. Finally, State Street Corp raised its holdings in Pacira Biosciences by 40.8% in the 3rd quarter. State Street Corp now owns 1,327,004 shares of the company’s stock valued at $50,519,000 after buying an additional 384,794 shares during the period.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Further Reading: How to build a Fibonacci channel

Analyst Recommendations for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.